全球心臟生物標記市場規模、佔有率、趨勢和成長分析報告（2026-2034）

全球心臟生物標記市場預計將從2025年的235億美元成長至2034年的658.5億美元，2026年至2034年的複合年成長率（CAGR）為12.13%。心血管疾病盛行率的不斷上升以及對早期診斷和個人化治療方法的日益重視，預計將推動心臟生物標記市場實現顯著成長。隨著醫療專業人員致力於改善患者預後，心臟生物標記在心臟疾病的診斷和管理中的作用日益重要。該市場涵蓋多種生物標記物，例如肌鈣蛋白、利鈉肽和其他能夠提供心臟健康重要資訊的蛋白質。人們對心臟疾病風險因素的認知不斷提高，以及對及時干預的迫切需求，正在推動該領域對先進診斷工具的需求。

技術進步在心臟生物標記市場的發展演變中發揮了至關重要的作用，即時檢測和臨床檢測的創新提高了心臟評估的速度和準確性。高靈敏度檢測方法和多參數檢測平台的開發使醫療專業人員能夠快速獲得全面的心臟狀況信息，從而有助於做出明智的決策。此外，遠端醫療醫療和遠端監測等數位健康技術的整合正在擴大心臟生物標記檢測的覆蓋範圍，尤其是在服務不足的人群中。隨著市場的成熟，那些優先考慮創新並投資於研發的公司有望佔據不斷成長的市場需求的更大佔有率。

此外，心臟生物標記市場日益受到監管趨勢和臨床指南的影響，這些趨勢和指南都在推動生物標記在心血管醫學中的應用。隨著醫療保健系統日益重視實證醫學，將心臟生物標記整合到常規臨床工作流程中變得越來越普遍。這種轉變正在推動對旨在發現新型生物標記並檢驗其臨床效用價值的研究舉措的投資。隨著對個人化醫療的日益關注，對能夠指導治療決策並改善患者預後的心臟生物標記的需求將會成長。能夠使其產品組合與臨床需求和監管要求相匹配的公司，將在這個充滿活力的市場中佔據有利地位，並取得成功。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為特定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別未來預期趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長地區和區域趨勢，以更深入地了解區域市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，以更好地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球心臟生物標記市場：按類型分類

• 市場分析、洞察與預測
• 心肌肌酸激酶（CK-MB）
• 肌鈣蛋白（T 型和 I 型）
• 肌紅蛋白
• 腦鈉肽 (BNP) 或 NT-proBNP
• 缺血修飾白蛋白（IMA）
• 其他

第5章 全球心臟生物標記市場：按應用分類

• 市場分析、洞察與預測
• 心肌梗塞
• 鬱血性心臟衰竭
• 急性冠狀動脈症候群
• 動脈硬化
• 其他

第6章 全球心臟生物標記市場：依檢測施行地點

• 市場分析、洞察與預測
• 即時檢測
• 臨床試驗

第7章 全球心臟生物標記市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 中國
  • 日本
  • 韓國
  • 印度
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • F. Hoffmann-La Roche AG
  • Siemens Healthineers AG
  • Abbott Laboratories
  • Thermo Fisher Scientific Inc
  • Danaher Corporation
  • Bio-Rad LaboratoriesInc
  • BioMerieux SA
  • QuidelOrtho Corporation
  • Randox Laboratories Ltd
  • Becton, Dickinson And Company
  • Tosoh Corporation
  • PerkinElmer Inc
  • Grifols SA
  • DiaSorin SpA
  • Sysmex Corporation
  • Lepu Medical Technology（Beijing）Co.Ltd
  • Mindray Bio-Medical Electronics Co.Ltd
  • Fujirebio Holdings Inc
  • Beckman CoulterInc
  • Trinity Biotech Plc

The global cardiac biomarkers market size is expected to reach USD 65.85 Billion in 2034 from USD 23.50 Billion in 2025, growing at a CAGR of 12.13% during 2026-2034.The Cardiac Biomarkers market is poised for significant growth, driven by the increasing prevalence of cardiovascular diseases and the growing emphasis on early diagnosis and personalized treatment approaches. As healthcare providers seek to improve patient outcomes, the role of cardiac biomarkers in diagnosing and managing heart conditions has become increasingly critical. This market encompasses a range of biomarkers, including troponins, natriuretic peptides, and other proteins that provide valuable insights into cardiac health. The rising awareness of heart disease risk factors and the need for timely intervention are propelling the demand for advanced diagnostic tools in this sector.

Technological advancements are playing a pivotal role in the evolution of the Cardiac Biomarkers market, with innovations in point-of-care testing and laboratory diagnostics enhancing the speed and accuracy of cardiac assessments. The development of high-sensitivity assays and multiplex testing platforms is enabling healthcare providers to obtain comprehensive cardiac profiles quickly, facilitating informed decision-making. Additionally, the integration of digital health technologies, such as telemedicine and remote monitoring, is expanding access to cardiac biomarker testing, particularly in underserved populations. As the market matures, companies that prioritize innovation and invest in research and development will likely capture a larger share of the growing demand.

Furthermore, the Cardiac Biomarkers market is increasingly influenced by regulatory developments and clinical guidelines that promote the use of biomarkers in cardiovascular care. As healthcare systems adopt evidence-based practices, the incorporation of cardiac biomarkers into routine clinical workflows is becoming more prevalent. This shift is driving investment in research initiatives aimed at discovering novel biomarkers and validating their clinical utility. As the focus on personalized medicine continues to grow, the demand for cardiac biomarkers that can guide treatment decisions and improve patient outcomes will expand. Companies that align their product offerings with clinical needs and regulatory requirements will be well-positioned to thrive in this dynamic market.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Type

• Myocardial Muscle Creatine Kinase (CK-MB)
• Troponins (T and I)
• Myoglobin
• Brain Natriuretic Peptide (BNPs) or NT-proBNP
• Ischemia Modified Albumin (IMA)
• Others

By Application

• Myocardial Infarction
• Congestive Heart Failure
• Acute Coronary Syndrome
• Atherosclerosis
• Others

By Location of Testing

• Point of Care Testing
• Laboratory Testing

COMPANIES PROFILED

• F. Hoffmann-La Roche AG, Siemens Healthineers AG, Abbott Laboratories, Thermo Fisher Scientific Inc., Danaher Corporation, Bio-Rad Laboratories, Inc., bioMerieux S.A., QuidelOrtho Corporation, Randox Laboratories Ltd., Becton, Dickinson and Company, Tosoh Corporation, PerkinElmer Inc., Grifols S.A., DiaSorin S.p.A., Sysmex Corporation, Lepu Medical Technology (Beijing) Co., Ltd., Mindray Bio-Medical Electronics Co., Ltd., Fujirebio Holdings Inc., Beckman Coulter, Inc., Trinity Biotech plc

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CARDIAC BIOMARKERS MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Myocardial Muscle Creatine Kinase (CK-MB) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Troponins (T and I) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Myoglobin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Brain Natriuretic Peptide (BNPs) or NT-proBNP Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Ischemia Modified Albumin (IMA) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CARDIAC BIOMARKERS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Myocardial Infarction Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Congestive Heart Failure Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Acute Coronary Syndrome Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Atherosclerosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CARDIAC BIOMARKERS MARKET: BY LOCATION OF TESTING 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Location Of Testing
• 6.2. Point of Care Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Laboratory Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CARDIAC BIOMARKERS MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Type
  • 7.2.2 By Application
  • 7.2.3 By Location Of Testing
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Type
  • 7.3.2 By Application
  • 7.3.3 By Location Of Testing
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Spain
  • 7.3.9 Russia
  • 7.3.10 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Type
  • 7.4.2 By Application
  • 7.4.3 By Location Of Testing
  • 7.4.4 China
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 India
  • 7.4.8 Australia
  • 7.4.9 South East Asia
  • 7.4.10 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Type
  • 7.5.2 By Application
  • 7.5.3 By Location Of Testing
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Type
  • 7.6.2 By Application
  • 7.6.3 By Location Of Testing
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CARDIAC BIOMARKERS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 F. Hoffmann-La Roche AG
  • 9.2.2 Siemens Healthineers AG
  • 9.2.3 Abbott Laboratories
  • 9.2.4 Thermo Fisher Scientific Inc
  • 9.2.5 Danaher Corporation
  • 9.2.6 Bio-Rad LaboratoriesInc
  • 9.2.7 BioMerieux S.A
  • 9.2.8 QuidelOrtho Corporation
  • 9.2.9 Randox Laboratories Ltd
  • 9.2.10 Becton, Dickinson And Company
  • 9.2.11 Tosoh Corporation
  • 9.2.12 PerkinElmer Inc
  • 9.2.13 Grifols S.A
  • 9.2.14 DiaSorin S.p.A
  • 9.2.15 Sysmex Corporation
  • 9.2.16 Lepu Medical Technology (Beijing) Co.Ltd
  • 9.2.17 Mindray Bio-Medical Electronics Co.Ltd
  • 9.2.18 Fujirebio Holdings Inc
  • 9.2.19 Beckman CoulterInc
  • 9.2.20 Trinity Biotech Plc